The Global Emergency Contraceptive Pills Market size is expected to grow from USD 1.04 billion in 2023 to USD 1.26 billion by 2032, at a CAGR of 2.11% during the forecast period (2024-2032).
Emergency contraception may be used to prevent pregnancy after unprotected sex. Emergency contraceptive pills (ECPs), also known as contraceptives, are pills that must be taken within 120 hours (5 days) of unprotected sex. In the late 1990s, the prescription Preven Emergency Contraception Kit was created. It was based on the Yuzpe method and included four combination pills, instructions, and a urine bioassay. Some emergency contraception is most effective when used within 72 hours (3 days) of intercourse. The emergency pill functions by delaying ovulation (the release of an egg during the monthly cycle). If fertilization and implantation have already occurred, ECPs will not terminate the pregnancy.
Top Key Players Covered In Emergency Contraceptive Pills Market
Bayer AG (Germany),Teva Pharmaceutical Industries Ltd. (Israel),HRL Laboratories, LLC (USA),Cipla Limited (India),Gedeon Richter Plc. (Hungary),Actavis Group PTC (Iceland),Laboratorios Andrómaco S.A. (Chile),Zhejiang Medicine Group Co., Ltd. (China),Laboratorio SIDI S.A. (Argentina),Hsieh's Holdings Limited (Hong Kong),Aspen Pharmacare Holdings Ltd. (South Africa),Wallace Pharmaceuticals Pty Ltd. (Australia),Wincon Medical Group Co., Ltd. (China),Shandong Lukang Pharmaceutical Group Co., Ltd. (China),Zhengzhou Pharmaceutical Factory Co., Ltd. (China),Chongqing Tianxin Pharmaceutical Co., Ltd. (China),Wuhan Huafei Pharmaceuticals Co., Ltd. (China),Xi'an Zhongmei Pharmaceutical Co., Ltd. (China),Jiangxi Kanbon Pharmaceutical Co., Ltd. (China),Chongqing Jialin Pharmaceutical Co., Ltd. (China).
Request a sample report @ https://introspectivemarketresearch.com/request/16296
Market Dynamics:
Driver:
The 99% pregnancy prevention guarantee is provided by contraceptive pills. The market for contraceptive drugs and devices is continuing to grow despite the sexual diseases that are rapidly growing. Emergency contraception pills prevent unintended pregnancy by preventing or delaying ovulation and do not induce abortion. This can propel the market of Emergency contraception pills.
Opportunities:
There will be expansion opportunities as a result of the quick uptake of generic contraceptives. Generic contraceptive pills are inexpensive and simple to use. The demand for generic contraceptive pills is rising as the number of abortions rises. Demand will increase as this market continues to develop. One of the major factors anticipated to hasten the growth of the global market for emergency contraceptive pills over the next few years is the increasing awareness of the public. In the coming years, the expansion of the market will likely be supported by the improvement of the distribution network and the easy accessibility of those pills.
Segmentation Analysis Of Emergency Contraceptive Pills Market:
By Product Type
· Progesterone Pills
· Estrogen Pills
· Combination Pills
By Distribution Channel
· Pharmacies
· E-Commerce
· Healthcare Facilities
Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert:
By Region
· North America (U.S., Canada, Mexico)
· Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
· Western Europe (Germany, U.K., France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
· Asia-Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
· Middle East & Africa (Turkey, Saudi Arabia, Bahrain, Kuwait, Qatar, UAE, Israel, South Africa)
· South America (Brazil, Argentina, Rest of SA)
Key Industry Developments in the Emergency Contraceptive Pills Market:
· In July 2023, Teva Pharmaceuticals acquired Anda Pharmaceuticals for $575 million. This acquisition strengthens Teva's position in the women's health market, giving them access to Anda's popular EC pill, NextChoice One-Step.
· In September 2023, private equity firm Advent International acquired a significant stake in HRA Pharma, the manufacturer of Ella, an emergency contraceptive pill known for its longer window of effectiveness. This investment aims to accelerate HRA Pharma's global expansion and product development.
Purchase this report:
About us:
Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assist our clients grow and have a successful impact on the market. Our team at IMR is ready to assist our clients flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, specialized in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyze extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.
Contact us:
Canada Office
Introspective Market Research Private Limited, 138 Downes Street Unit 6203- M5E 0E4, Toronto, Canada.
APAC Office
Introspective Market Research Private Limited, Office No. 401-403, Saudamini Commercial Complex, Chandani Chowk, Kothrud, Pune India 411038
Ph no: +1-773-382-1049
Comments